WCA
SRNE

Windsor Creek Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Windsor Creek Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,000
Closed -$28K – 215
2020
Q1 		$28K Buy
+15,000
New +$43.2K 0.01% 165

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Windsor Creek Advisors's SRNE Position: Q2 2020 in Review

Windsor Creek Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2020, closing a stake of 15,000 shares — an estimated $28K sold.

Windsor Creek Advisors first reported a position in SRNE in Q1 2020 and held it in 1 quarter. The position peaked at $28K in Q1 2020. 186 funds tracked by Wall St. Rank hold SRNE as of Q2 2020.

  • Windsor Creek Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 15,000 Sorrento Therapeutics, Inc. shares in Q2 2020, an estimated $28K.
  • Windsor Creek Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Windsor Creek Advisors's Sorrento Therapeutics, Inc. position peaked at $28K in Q1 2020.
  • 186 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2020.

Based on Windsor Creek Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.